<DOC>
	<DOCNO>NCT02661152</DOCNO>
	<brief_summary>Hypoxic modification radiotherapy nimorazole previously show increase radiosensitivity hypoxic head neck squamous cell carcinoma ( HNSCC ) . In Denmark , nimorazole add radiotherapy HNSCC , previously possible discriminate hypoxic tumours less hypoxic tumour . A hypoxia gene profile show discriminate responder non-responders nimorazole . In DAHANCA 30 , expect hypoxia profile guide non-responders randomize +/- nimorazole radiotherapy.This order verify clinical use gene profile select relevant patient hypoxic modification radiotherapy nimorazole .</brief_summary>
	<brief_title>DAHANCA 30 : A Randomized Non-inferiority Trial Hypoxia-profile Guided Hypoxic Modification Radiotherapy HNSCC .</brief_title>
	<detailed_description>Hypoxic modification radiotherapy nimorazole DAHANCA 5 trial show increase radiosensitivity hypoxic head neck squamous cell carcinoma ( HNSCC ) . Previously , possible discriminate hypoxic tumours less hypoxic tumour . Thus , nimorazole add radiotherapy HNSCC . Recently , hypoxia gene profile develop , discriminate less hypoxic tumour . The basis discrimination cumulate expression 15 hypoxia responsive gene , quantify tumour biopsy . The profile validate independent DAHANCA 5 cohort . There significant effect add nimorazole radiotherapy hypoxic tumour estimate gene profile , whereas effect add nimorazole less hypoxic tumour . In test interaction , significantly different response nimorazole hypoxic tumour compare less hypoxic tumour . In Dahanca 30 trial aim verify , benefit supply radiotherapy less hypoxic HNSCC nimorazole . Thus , explore whether possible avoid sideeffects nimorazole without risk patient .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Anoxia</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Nimorazole</mesh_term>
	<criteria>Head neck squamous cell carcinoma indication hypoxic modification nimorazole accordance Danish Head Neck Cancer guideline ( DAHANCA guideline ) . Informed consent Previous present malignant disease conflict radiotherapy treatment evaluation treatment . Participation conflict protocol . Initiation radiotherapy 3 week inclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>